These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 33151040)

  • 41. CIM6P/IGF-2 Receptor Ligands Reverse Deficits in Angelman Syndrome Model Mice.
    Cruz E; Descalzi G; Steinmetz A; Scharfman HE; Katzman A; Alberini CM
    Autism Res; 2021 Jan; 14(1):29-45. PubMed ID: 33108069
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gait as a quantitative translational outcome measure in Angelman syndrome.
    Petkova SP; Adhikari A; Berg EL; Fenton TA; Duis J; Silverman JL
    Autism Res; 2022 May; 15(5):821-833. PubMed ID: 35274462
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Angelman syndrome: Current and emerging therapies in 2016.
    Tan WH; Bird LM
    Am J Med Genet C Semin Med Genet; 2016 Dec; 172(4):384-401. PubMed ID: 27860204
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Decreased tonic inhibition in cerebellar granule cells causes motor dysfunction in a mouse model of Angelman syndrome.
    Egawa K; Kitagawa K; Inoue K; Takayama M; Takayama C; Saitoh S; Kishino T; Kitagawa M; Fukuda A
    Sci Transl Med; 2012 Dec; 4(163):163ra157. PubMed ID: 23220633
    [TBL] [Abstract][Full Text] [Related]  

  • 45. From electrophysiology to chromatin: a bottom-up approach to Angelman syndrome.
    Dan B; Servais L; Boyd SG; Wagstaff J; Cheron G
    Ann N Y Acad Sci; 2004 Dec; 1030():599-611. PubMed ID: 15659843
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Early Developmental EEG and Seizure Phenotypes in a Full Gene Deletion of Ubiquitin Protein Ligase E3A Rat Model of Angelman Syndrome.
    Born HA; Martinez LA; Levine AT; Harris SE; Mehra S; Lee WL; Dindot SV; Nash KR; Silverman JL; Segal DJ; Weeber EJ; Anderson AE
    eNeuro; 2021; 8(2):. PubMed ID: 33531368
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HAP1 is an in vivo UBE3A target that augments autophagy in a mouse model of Angelman syndrome.
    Wang T; Wang J; Wang J; Mao L; Tang B; Vanderklish PW; Liao X; Xiong ZQ; Liao L
    Neurobiol Dis; 2019 Dec; 132():104585. PubMed ID: 31445164
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Atypical cases of Angelman syndrome.
    Lawson-Yuen A; Wu BL; Lip V; Sahoo T; Kimonis V
    Am J Med Genet A; 2006 Nov; 140(21):2361-4. PubMed ID: 17036311
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Distinct phenotypes distinguish the molecular classes of Angelman syndrome.
    Lossie AC; Whitney MM; Amidon D; Dong HJ; Chen P; Theriaque D; Hutson A; Nicholls RD; Zori RT; Williams CA; Driscoll DJ
    J Med Genet; 2001 Dec; 38(12):834-45. PubMed ID: 11748306
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mouse models of Angelman syndrome, a neurodevelopmental disorder, display different brain regional GABA(A) receptor alterations.
    Sinkkonen ST; Homanics GE; Korpi ER
    Neurosci Lett; 2003 Apr; 340(3):205-8. PubMed ID: 12672542
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Loss of Angelman Syndrome Protein E6AP Disrupts a Novel Antagonistic Estrogen-Retinoic Acid Transcriptional Crosstalk in Neurons.
    El Hokayem J; Weeber E; Nawaz Z
    Mol Neurobiol; 2018 Sep; 55(9):7187-7200. PubMed ID: 29388081
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Maternal Loss of Ube3a Impairs Experience-Driven Dendritic Spine Maintenance in the Developing Visual Cortex.
    Kim H; Kunz PA; Mooney R; Philpot BD; Smith SL
    J Neurosci; 2016 Apr; 36(17):4888-94. PubMed ID: 27122043
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [From pathogenesis to treatment of genetic intellectual disabilities: a lesson from Angelman syndrome research].
    Saitoh S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2013 Jun; 33(3):127-30. PubMed ID: 25069246
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mutation Update for UBE3A variants in Angelman syndrome.
    Sadikovic B; Fernandes P; Zhang VW; Ward PA; Miloslavskaya I; Rhead W; Rosenbaum R; Gin R; Roa B; Fang P
    Hum Mutat; 2014 Dec; 35(12):1407-17. PubMed ID: 25212744
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Angelman syndrome reviewed from a neurophysiological perspective. The UBE3A-GABRB3 hypothesis.
    Dan B; Boyd SG
    Neuropediatrics; 2003 Aug; 34(4):169-76. PubMed ID: 12973656
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Angelman Syndrome due to a Maternally Inherited Intragenic Deletion Encompassing Exons 7 and 8 of the UBE3A Gene.
    Ververi A; Islam L; Bewes B; Busby L; Sullivan C; Canham N
    Cytogenet Genome Res; 2017; 152(3):132-136. PubMed ID: 28898887
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impaired adult hippocampal neurogenesis and its partial reversal by chronic treatment of fluoxetine in a mouse model of Angelman syndrome.
    Godavarthi SK; Dey P; Sharma A; Jana NR
    Biochem Biophys Res Commun; 2015 Sep; 464(4):1196-1201. PubMed ID: 26231800
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mice lacking the beta3 subunit of the GABAA receptor have the epilepsy phenotype and many of the behavioral characteristics of Angelman syndrome.
    DeLorey TM; Handforth A; Anagnostaras SG; Homanics GE; Minassian BA; Asatourian A; Fanselow MS; Delgado-Escueta A; Ellison GD; Olsen RW
    J Neurosci; 1998 Oct; 18(20):8505-14. PubMed ID: 9763493
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Angelman syndrome due to a novel splicing mutation of the UBE3A gene.
    Sartori S; Anesi L; Polli R; Toldo I; Casarin A; Drigo P; Murgia A
    J Child Neurol; 2008 Aug; 23(8):912-5. PubMed ID: 18487518
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neurodevelopmental outcome in Angelman syndrome: genotype-phenotype correlations.
    Mertz LG; Thaulov P; Trillingsgaard A; Christensen R; Vogel I; Hertz JM; Ostergaard JR
    Res Dev Disabil; 2014 Jul; 35(7):1742-7. PubMed ID: 24656292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.